Bone Biologics Corp Stock Performance
| BBLGW Stock | USD 27.80 0.69 2.42% |
Bone Biologics holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -3.92, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bone Biologics are expected to decrease by larger amounts. On the other hand, during market turmoil, Bone Biologics is expected to outperform it. Use Bone Biologics variance, skewness, as well as the relationship between the Skewness and day typical price , to analyze future returns on Bone Biologics.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Bone Biologics Corp are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile technical and fundamental indicators, Bone Biologics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.92 | Five Day Return (2.42) | Year To Date Return 603.8 | Ten Year Return (22.13) | All Time Return (22.13) |
Last Split Factor 1:30 | Last Split Date 2023-06-07 |
1 | BBLG stock touches 52-week low at 1 amid steep annual decline - Investing.com | 09/13/2024 |
2 | Long Term Trading Analysis for - Stock Traders Daily | 10/28/2024 |
3 | Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 | 11/01/2024 |
4 | Acquisition by Booth John J of 26780 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | 11/26/2024 |
5 | Acquisition by Hankey Don of 1063830 shares of Bone Biologics subject to Rule 16b-3 | 11/27/2024 |
| Begin Period Cash Flow | 7.5 M |
Bone |
Bone Biologics Relative Risk vs. Return Landscape
If you would invest 6,050 in Bone Biologics Corp on August 31, 2024 and sell it today you would lose (3,270) from holding Bone Biologics Corp or give up 54.05% of portfolio value over 90 days. Bone Biologics Corp is currently producing 1.3361% returns and takes up 24.2923% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Bone, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Bone Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bone Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bone Biologics Corp, and traders can use it to determine the average amount a Bone Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.055
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | BBLGW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 24.29 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.34 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Bone Biologics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bone Biologics by adding it to a well-diversified portfolio.
Bone Biologics Fundamentals Growth
Bone Stock prices reflect investors' perceptions of the future prospects and financial health of Bone Biologics, and Bone Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bone Stock performance.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 | ||||
| EBITDA | 479.57 K | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 4.44 K | ||||
| Total Debt | 831.4 K | ||||
| Book Value Per Share | 5.44 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | (0.14) X | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
About Bone Biologics Performance
Evaluating Bone Biologics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Bone Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bone Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 368.20 | 327.29 | |
| Return On Tangible Assets | (2.39) | (2.51) | |
| Return On Capital Employed | (3.24) | (3.08) | |
| Return On Assets | (2.39) | (2.51) | |
| Return On Equity | (3.08) | (2.93) |
Things to note about Bone Biologics Corp performance evaluation
Checking the ongoing alerts about Bone Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bone Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bone Biologics Corp is way too risky over 90 days horizon | |
| Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp has accumulated about 4.44 K in cash with (9.56 M) of positive cash flow from operations. | |
| Latest headline from MacroaxisInsider: Acquisition by Hankey Don of 1063830 shares of Bone Biologics subject to Rule 16b-3 |
- Analyzing Bone Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bone Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Bone Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bone Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bone Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bone Biologics' stock. These opinions can provide insight into Bone Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.